What is Rybelsus used for?

Rybelsus contains oral semaglutide and is authorised for type 2 diabetes. Any use in a weight-management pathway must be an individual, doctor-led decision and may be off-label.

What side effects can Rybelsus cause?

Nausea, diarrhoea, vomiting, abdominal pain and reduced appetite are common. Severe persistent abdominal pain or dehydration needs prompt medical review.

What does the doctor check before prescribing Rybelsus?

The doctor reviews diabetes treatment, pancreatitis and gallbladder history, eye disease, kidney function, pregnancy plans and other medicines that affect glucose.

Can I get a consultation for Rybelsus from Lyon?

Yes. Hi-Doctor runs 100 % online across the EU, so if you live in Lyon you can fill in the questionnaire and receive the medical review without travelling. The electronic prescription issued by the licensed doctor is valid in any EU pharmacy under Directive 2011/24/EU; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.

Who is a candidate for a medical weight-management programme?

Adults with BMI ≥ 30, or ≥ 27 with comorbidities (hypertension, type-2 diabetes, dyslipidaemia). The doctor reviews your history, current medication and goals before proposing any treatment. It is not a cosmetic programme.

What is the private electronic prescription and why is it valid across the EU?

The private electronic prescription (Receta Médica Privada Electrónica) is issued by a licensed doctor in Spain. It is a PDF carrying every field required by EU Directive 2011/24/EU (patient, prescriber with country of registration, active ingredient, dose), which makes it legally recognised across all 27 EU member states. In Spanish pharmacies it is dispensed from the QR; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.

How does Hi-Doctor work step by step?

1) Fill in an online medical questionnaire in about 4 minutes. 2) The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; sexual health is €35 per consultation and a skin consultation is €40. 3) An EU-licensed doctor reviews your case and, if appropriate, issues an electronic prescription. 4) Collect it at any EU pharmacy. If the review is not approved, the applicable fee is refunded in full.

How much does it cost and what does the price include?

The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; a one-off sexual-health consultation is €35 and a skin consultation — acne, rosacea, melasma, ageing skin — is €40. Each includes a licensed doctor's review and an electronic prescription if approved. If the review is not approved, the applicable fee is refunded in full. Medication is paid for separately at the pharmacy at the price it sets.

Rybelsus · LyonPrescription only

Online medical consultation for Rybelsus in Lyon.

An EU-licensed doctor reviews your case and, if eligible, issues an electronic prescription valid in any pharmacy in France. Consultation €25/month, refunded if the doctor decides it is not safe to prescribe.

Rybelsus pack shot — a prescription medicine an EU-licensed doctor can prescribe online after a Hi-Doctor consultation in Lyon.

Tablet formulation
Gradual escalation
Metabolic review

Start consultationStart consultation · €25/month

Full refund if a review is not approved · Medication, if prescribed, is dispensed and paid for separately at a pharmacy.

IN PLAIN TERMS

What Rybelsus is, and how to get treatment

Rybelsus is a tablet form of semaglutide. It is licensed in the European Union, but only for one thing: controlling blood sugar in adults with type 2 diabetes. It is not licensed in the EU as a weight-loss medicine. People taking it for diabetes often lose some weight as a side effect, and that is where its reputation as a weight-loss pill comes from, but prescribing Rybelsus purely to lose weight is off-label, meaning it is being used outside what regulators have assessed and approved. A separate, higher-dose oral semaglutide tablet was authorised in the EU for weight management in July 2026, so if you are looking for a semaglutide tablet for weight, that is a different product and a doctor should decide what is appropriate for you.

Rybelsus has been authorised for use in the EU since 3 April 2020, so a licensed doctor can prescribe it when it is clinically appropriate for you.

Learn more about peptides at Peptidepedia.

Can I get it?

Yes, if a doctor decides it is right for you. Rybelsus is authorised in the EU and can be prescribed after a medical review.

What can I take instead?

Our doctors review every Weight loss option and recommend what fits your history and goals.

See all Weight loss options

What do the studies show?

Every trial behind Rybelsus is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.

Jump to the studies

Local consultation facts

Can I get Rybelsus in Lyon?

Yes. People in Lyon, France, can request an online doctor consultation about Rybelsus with Hi-Doctor. A licensed EU doctor reviews the case and issues a prescription only when clinically appropriate. If approved, the EU prescription arrives as a PDF for a pharmacist in France, who dispenses the locally marketed equivalent containing Oral-semaglutide.

Availability

Rybelsus is available to residents of France through the online consultation. A prescription follows only if the doctor approves it.

Country: France
Language of service: Spanish and English
Prescription turnaround: In less than 4 hours on average, only if the doctor approves
Honoured locally: PDF honoured locally for an equivalent containing Oral-semaglutide

How the EU prescription works where you are: In France, show the approved prescription PDF to a pharmacist. They honour it under EU cross-border rules and dispense the locally marketed equivalent containing Oral-semaglutide.

VERIFIED EVIDENCE

Rybelsus: evidence and regulatory guide.

WHAT IT IS

How it works

A daily tablet containing semaglutide, a copy of the gut hormone GLP-1, which helps the body release insulin after meals and lowers blood sugar.

GLP-1

DEVELOPMENT STAGE

EU-authorised medicine

Trial register1 registered trials

Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.

Registered trials for Rybelsus
TRIAL / NCT	POPULATION	PARTICIPANTS	STATUS	READOUT / COMPLETION
PIONEER 4NCT02863419	Adults with type 2 diabetes not adequately controlled on metformin, with or without an SGLT-2 inhibitor	711	Read out	—

What the studies reported

Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.

Peer-reviewed

Pratley RE, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4). Lancet. 2019. doi:10.1016/S0140-6736(19)31271-1 (PMID 31186120)

Pratley RE, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4). Lancet. 2019. doi:10.1016/S0140-6736(19)31271-1 (PMID 31186120)
DOSE OR GROUP	MEAN WEIGHT CHANGE	WEEKS
Oral semaglutide 14 mg daily	−4.7 kg body weight	26
Oral semaglutide 14 mg daily	−5.0 kg body weight	52
Liraglutide 1.8 mg daily by injection (comparator arm)	−3.1 kg body weight	52
Placebo	−1.2 kg body weight	52

PIONEER 4 was a type 2 diabetes trial whose main purpose was to measure blood-sugar control; weight change was a secondary measurement in people with diabetes, not a test of Rybelsus as a weight-loss treatment, and Rybelsus has no EU weight-management indication.

Sources

Last reviewed 2026-07-27

NAMED SAFETY SIGNALS

What has been reported with Rybelsus.

Nausea

Very common in the Rybelsus product information, reported in around 15% of people taking semaglutide; usually mild to moderate and settling over time.

Diarrhoea

Very common in the Rybelsus product information, reported in around 10% of people taking semaglutide.

Vomiting

Reported in around 7% of people taking semaglutide in the Rybelsus product information.

Off-label use for weight loss

Rybelsus is authorised in the EU only for type 2 diabetes. Prescribing it purely for weight loss falls outside its authorised indication, so the EU-assessed benefit-risk balance for that use has not been established.

FormOral tablet

FrequencyOnce daily

ResultsGradual, assessed over months

StatusPrescription only

About

What is Rybelsus?

Active ingredient: Oral-semaglutide · Dosages: 1.5–9 mg daily formulation

Rybelsus contains oral semaglutide and is authorised for adults with type 2 diabetes. Any place in a weight-management pathway is an individual doctor-led decision and may be off-label.

The indication, regimen and follow-up depend on your history and country guidance. A licensed doctor decides whether it is appropriate; prescribing is never automatic.

How it works in the body

Semaglutide activates GLP-1 receptors, supporting glucose-dependent insulin release, reducing glucagon and slowing stomach emptying. Appetite may also decrease.

How it helps

What it can offer when appropriate.

Tablet formulation

It provides semaglutide without an injection, but requires precise fasting administration.

Gradual escalation

Starting low helps the body adapt before a maintenance dose is considered.

Metabolic review

Glucose treatment, appetite, weight and adverse effects are reviewed together.

What to expect

A doctor-defined regimen.

It is taken after an overnight fast with up to 120 ml of water, followed by at least 30 minutes before food, drink or other oral medicines. The dose is increased gradually.

Start · 1.5 mg once daily for one month
Step up · 4 mg once daily if appropriate
Review · Consider 9 mg only after at least one month

Typical regimen

Starting dose1.5 mg once daily
Maintenance options4 mg or 9 mg once daily

Your schedule is personal

These are typical steps only. Your doctor adjusts the plan to how you respond and tolerate it — and you can message them at any point.

Safety first

Safety, in full.

Rybelsus is an effective medicine — and like any medicine it carries risks. Your doctor screens for all of this before prescribing. Here's the honest picture, not just reassurance.

Nausea, diarrhoea, vomiting, abdominal pain and reduced appetite are common.

Not suitable if you

You are pregnant, breastfeeding or planning pregnancy
A history of serious semaglutide reaction or an unresolved pancreatic or gastrointestinal concern makes it unsuitable

When to seek urgent care

For severe, sudden or unexpected symptoms, call your local emergency number or go to the nearest emergency department. Then let your doctor know through your account chat.

PRICING

You only pay if treatment is approved.

€25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth. One-off consultations are €35 for sexual health and €40 for dermatology.